Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

Blood (2016) 128 (22): 3276.

https://doi.org/10.1182/blood.V128.22.3276.3276

Published: 2016

Journal Articles

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Mark A Fiala, BS, CCRP, Jesse Keller, MD, Jeevan Sekhar, MD, Connie Ceriotti, RN, BSN, Camille N. Abboud, MD, John F DiPersio, MD PhD, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Keith Stockerl-Goldstein, Ravi Vij, MD MBA

Blood (2016) 128 (22): 3329.

https://doi.org/10.1182/blood.V128.22.3329.3329

Published: 2016

Journal Articles

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma

Armin Ghobadi, MD, Mark A Fiala, BS, CCRP, Geoffrey L. Uy, MD, Keith Stockerl-Goldstein, Ravi Vij, MD MBA, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3381.

https://doi.org/10.1182/blood.V128.22.3381.3381

Published: 2016

Journal Articles

The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant

Justin A King, Mark A Fiala, BS, CCRP, Daniel R Kohnen, Tanya M Wildes, MD, Keith Stockerl-Goldstein, Ravi Vij, MD MBA

Blood (2016) 128 (22): 3563.

https://doi.org/10.1182/blood.V128.22.3563.3563

Published: 2016

Journal Articles

Age and Health Status Determine Treatment Receipt in Patients with Multiple Myeloma

Bita Fakhri, MD MPH, Mark A Fiala, BS, CCRP, Sascha Tuchman, MD, Tanya M Wildes, MD

Blood (2016) 128 (22): 2348.

https://doi.org/10.1182/blood.V128.22.2348.2348

Published: 2016

Journal Articles

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Daniel Auclair, PhD, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2349.

https://doi.org/10.1182/blood.V128.22.2349.2349

Published: 2016

Journal Articles

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Mark A Fiala, BS, CCRP, James Dukeman, BS, Keith Stockerl-Goldstein, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Ravi Vij, MD MBA

Blood (2016) 128 (22): 2350.

https://doi.org/10.1182/blood.V128.22.2350.2350

Published: 2016

Journal Articles

Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances

Leylah Drusbosky, PhD, Mark A Fiala, BS, CCRP, Justin A King, Ravi Vij, MD MBA, Shireen Vali, PhD, Taher Abbasi, Neeraj Kumar Singh, Ansu Kumar, Saji Gera, Christopher R. Cogle, MD

Blood (2016) 128 (22): 2099.

https://doi.org/10.1182/blood.V128.22.2099.2099

Published: 2016

Journal Articles

Uncovering Clonal and Subclonal Druggable Targets in Multiple Myeloma Using Omic Data

Adam David Scott, PhD, Venkata D Yellapantula, PhD, Christopher J Yoon, BS, Michael Wendl, PhD, Michael H. Tomasson, MD, Mark A Fiala, BS, CCRP, John F. DiPersio, MD, PhD, Ravi Vij, MD, Li Ding, PhD

Blood (2016) 128 (22): 2084.

https://doi.org/10.1182/blood.V128.22.2084.2084

Published: 2016

Journal Articles

Racial Disparities in Treatment Utilization for Multiple Myeloma

Mark A Fiala, BS, CCRP, James Dukeman, BS, Tanya M Wildes, MD MSCI

Blood (2016) 128 (22): 844.

https://doi.org/10.1182/blood.V128.22.844.844

Published: 2016

Journal Articles

The Association of International Staging System (ISS) Stage with Disease and Symptom Burden in Patients with Newly Diagnosed Multiple Myeloma

Mark A Fiala, BS, CCRP, Michael Slade, BA, Jesse Keller, MD, Keith Stockerl-Goldstein, MD, Michael Tomasson, MD, Tanya M Wildes, MD MSCI, Ravi Vij, MD MBA

Blood (2015) 126 (23): 2115.

https://doi.org/10.1182/blood.V126.23.2115.2115

Published: 2015

Journal Articles

A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma

Mark A Fiala, BS, CCRP, David Schwab, BA CCRP, Ravi Vij, MD MBA, Amanda F. Cashen, MD, Keith Stockerl-Goldstein, MD, Camille N. Abboud, MD

Blood (2015) 126 (23): 516.

https://doi.org/10.1182/blood.V126.23.516.516

Published: 2015

Journal Articles

Falls in Older Adults with Multiple Myeloma

Tanya M Wildes, MD MSCI, Mark A Fiala, BS, CCRP, Ashley E Rosko, MD, Sascha Tuchman, MD, Emily Guerard, MD, Elizabeth K. O'Donnell, MD, Erica L. Campagnaro, MD, Keith Stockerl-Goldstein, MD, Ravi Vij, MD MBA

Blood (2015) 126 (23): 4485.

https://doi.org/10.1182/blood.V126.23.4485.4485

Published: 2015

Journal Articles

Presenting Characteristics and Symptom Burden of Newly Diagnosed Older Multiple Myeloma Patients in the Commpass Study

Jesse Keller, MD, Mark A Fiala, BS, CCRP, Michael Slade, BA, Keith Stockerl-Goldstein, MD, Michael Tomasson, MD, Tanya M Wildes, MD MSCI, Ravi Vij, MD MBA

Blood (2015) 126 (23): 3307.

https://doi.org/10.1182/blood.V126.23.3307.3307

Published: 2015

Journal Articles

A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants

Brian S White, PhD, Irena Lanc, PhD, Daniel Auclair, PhD, Robert Fulton, PhD, Mark A Fiala, BS, CCRP, Justin King, Gregory Ahmann, BS, Mary Derome, MS, Elaine R Mardis, PhD, Joan Levy, PhD, Ravi Vij, MD MBA, John F. DiPersio, MD PhD, Michael Tomasson, MD

Blood (2015) 126 (23): 4207.

https://doi.org/10.1182/blood.V126.23.4207.4207

Published: 2015

Journal Articles

The Association Between Performance Status and Health-Related Quality of Life

Mark A Fiala, BS, CCRP, Jesse Keller, MD, Michael Slade, BA, Keith Stockerl-Goldstein, MD, Michael Tomasson, MD, Ravi Vij, MD MBA, Tanya M Wildes, MD MSCI

Blood (2015) 126 (23): 3312.

https://doi.org/10.1182/blood.V126.23.3312.3312

Published: 2015

Journal Articles

Variations in Multiple Myeloma Disease Presentation By Race

Mark A Fiala, BS, CCRP, Tanya M Wildes, MD MSCI, Michael Slade, BA, Jesse Keller, MD, Keith Stockerl-Goldstein, MD, Michael Tomasson, MD, Ravi Vij, MD MBA

Blood (2015) 126 (23): 5618.

https://doi.org/10.1182/blood.V126.23.5618.5618

Published: 2015

Journal Articles

CD34 + -Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant

Armin Ghobadi, MD, Mark A Fiala, BS, CCRP, Giridharan Ramsingh, MD, Feng Gao, PhD, Camille N. Abboud, MD, Keith Stockerl-Goldstein, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, John F. DiPersio, MD PhD

Blood (2015) 126 (23): 3098.

https://doi.org/10.1182/blood.V126.23.3098.3098

Published: 2015

Journal Articles

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Jesse Keller, MD, Mark A Fiala, BS, CCRP, Jeevan Sekhar, Connie Ceriotti, Melissa Allen, Camille N. Abboud, MD, Keith E. Stockerl-Goldstein, MD, Tanya M Wildes, MD MSCI, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD

Blood (2014) 124 (21): 4731.

https://doi.org/10.1182/blood.V124.21.4731.4731

Published: 2014

Journal Articles

Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status

Mark A. Fiala, BS, CCRP, Jesse Keller, MD, Keith E. Stockerl-Goldstein, MD, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD, Tanya M Wildes, MD MSCI

Blood (2014) 124 (21): 555.

https://doi.org/10.1182/blood.V124.21.555.555

Published: 2014

NARROW

IgM Myeloma: A Multicenter Retrospective Study of 159 Patients

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination with G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma

The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant

Age and Health Status Determine Treatment Receipt in Patients with Multiple Myeloma

Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma

The Real-World Characteristics and Outcomes of Newly Diagnosed Myeloma Patients Ineligible for Clinical Trials

Use of Genomic Information to Predict Treatment Response in Multiple Myeloma Patients By Computational Mapping of Protein Network Disturbances

Uncovering Clonal and Subclonal Druggable Targets in Multiple Myeloma Using Omic Data

Racial Disparities in Treatment Utilization for Multiple Myeloma

The Association of International Staging System (ISS) Stage with Disease and Symptom Burden in Patients with Newly Diagnosed Multiple Myeloma

A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma

Falls in Older Adults with Multiple Myeloma

Presenting Characteristics and Symptom Burden of Newly Diagnosed Older Multiple Myeloma Patients in the Commpass Study

A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants

The Association Between Performance Status and Health-Related Quality of Life

Variations in Multiple Myeloma Disease Presentation By Race

CD34 + -Selected Infusions of Fresh or Cryopreserved Peripheral Blood Stem Cells for the Treatment of Poor Graft Function Following Allogeneic Hematopoietic Stem Cell Transplant

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only